bio sketch column
Chris joined Apple Tree Partners in 2016 as an Associate focused on therapeutics. Prior to joining Apple Tree, Chris was an Associate at RA Capital Management, LLC, a crossover fund invested in healthcare and the life sciences. Previously, Chris was a writer and editor at BioCentury Publications and the Science-Business eXchange (SciBX), a translational science journal co-published with Nature Publishing Group, where he evaluated the clinical and commercial potential of novel molecular targets and drug platforms emerging from academic labs. Prior to BioCentury, Chris was a researcher at the UCSF, where his work focused on understanding the transcriptional regulation and evolution of morphological change in fungi including the pathogen Candida albicans.
Chris holds a BA in Biology from the UC Santa Barbara. He earned his PhD in Biochemistry and Molecular Biology from the UCSF, where he was awarded a Genentech Graduate Fellowship.